Ani Pharmaceuticals reported $27.65M in Gross Profit on Sales for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Aerie Pharmaceuticals AERI:US $ 21.41M 0.41M
Ani Pharmaceuticals ANIP:US $ 27.65M 1.34M
Aurora Cannabis Inc ACB:CN 14.1M 75.17M
Canopy Growth Corp WEED:CN C$ -71140000 98.38M
Depomed DEPO:US $ 22.42M 0.97M
Eli Lilly And LLY:US $ 5342M 555.1M
Emergent Biosolutions EBS:US $ 111.5M 58.2M
Endo International Ordinary Shares ENDP:US $ 474.91M 74.51M
Flexion Therapeutics FLXN:US $ 17.6M 5.6M
Hikma Pharmaceutical HIK:LN 616M 5M
Knight Therapeutics Inc GUD:CN C$ 37.77M 8.9M
Lannett LCI:US $ 16.52M 6.14M
Nektar Therapeutics NKTR:US $ 19.61M 1.05M
Novartis NVS:US $ 9519M 21M
Omeros OMER:US $ 29.67M 1.19M
Perrigo Ordinary Shares PRGO:US $ 336.4M 12.6M
Sun Pharmaceuticals SUNP:IN IR 71040.7M 347.6M
Teva Pharmaceutical TEVA:IT 1.9B 25M
Teva Pharmaceutical Industries TEVA:US $ 1898M 25M